Corbus Pharmaceuticals

Corbus Pharmaceuticals Appoints Rachelle Jacques to Board of Directors

Ziad2022-11-25T14:03:38-05:00 Corbus Pharmaceuticals Holdings, Inc. today announced the appointment of Rachelle Jacques to its Board of Directors. <a href="https://www.globenewswire.com/news-release/2019/04/08/1799009/0/en/Corbus-Pharmaceuticals-Appoints-Rachelle-Jacques-to-Board-of-Directors.html" target="_blank">Read more >></a>

Corbus Pharmaceuticals Provides Management Team Updates

Ziad2022-11-25T14:03:38-05:00 Corbus Pharmaceuticals Holdings, Inc. today announced several changes to its management team. Read more >>

Corbus Pharmaceuticals Announces Appointment of Craig Millian as Chief Commercial Officer

Ziad2022-11-25T14:03:39-05:00 Corbus Pharmaceuticals Holdings, Inc. today announced the appointment of Craig Millian as Chief Commercial Officer, effective February 28, 2019. Read more >>

Corbus Pharmaceuticals Announces Strategic Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Lenabasum in Japan for Systemic Sclerosis and Dermatomyositis

Ziad2022-11-25T14:04:53-05:00Corbus Pharmaceuticals Holdings, Inc. announced today that they have entered into a strategic collaboration with Kaken Pharmaceutical Co., Ltd. ("Kaken") for the development and commercialization in Japan of Corbus' investigational drug lenabasum for the treatment of systemic sclerosis ("SSc") and dermatomyositis ("DM"), two rare and serious autoimmune diseases. Read more >>

Corbus Pharma (CRBP) Announces Issuance of Composition of Matter Patent Related to Lenabasum

Ziad2022-11-25T14:04:53-05:00Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical stage drug development company with the industry’s leading pipeline focused on treating inflammatory and fibrotic diseases by targeting the endocannabinoid system, announced today that the U.S. Patent and Trademark Office (“USPTO”) issued Patent No. 10,154,986 to the Company which claims pharmaceutical compositions of lenabasum through 2034. Read more >>

Corbus Pharmaceuticals Presents Lenabasum Long-Term Open-Label Clinical Data Showing Maintenance of Favorable Safety Profile and Further Improvement in Multiple Efficacy Endpoints in Systemic Sclerosis and Dermatomyositis Phase 2 Studies

Ziad2022-11-25T14:04:54-05:00Corbus Pharmaceuticals Holdings, Inc., a clinical stage drug development company with the industry’s leading pipeline focused on treating inflammatory and fibrotic diseases by targeting the endocannabinoid system, today announced continued favorable safety and tolerability profiles and further improvement in efficacy outcomes in open-label extensions (OLEs) of lenabasum Phase 2 studies in two rare and serious autoimmune diseases, systemic sclerosis (SSc) and dermatomyositis (DM). Read more >>

Corbus Awarded US Patent Covering Lenabasum as Potential CF and Fibrotic Disease Treatment

Ziad2022-11-25T14:04:54-05:00Corbus Pharmaceuticals has received a patent from the U.S. Patent and Trademark Office covering all compositions that comprise lenabasum and might be used to treat any fibrotic disease, including cystic fibrosis (CF), the company announced in a press release. Read more >>

Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in October

Ziad2022-11-25T14:04:54-05:00Corbus Pharmaceuticals Holdings, Inc., a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its industry leading pipeline of endocannabinoid system-targeting drug candidates, announced today that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present at two upcoming investor conferences in October. Read more >>

Corbus Pharmaceuticals receives Orphan Designation for lenabasum for the treatment of DM in EU

Ziad2022-11-25T14:04:54-05:00Corbus Pharmaceuticals announces that the European Commission has granted Orphan Designation in the European Union (EU) to lenabasum, its synthetic oral endocannabinoid-mimetic drug, for the treatment of dermatomyositis (DM). Read more >>

Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2018 ACR Annual Meeting

Ziad2022-11-25T14:04:54-05:00Corbus Pharmaceuticals Holdings, Inc., a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases, announced today that its abstracts have been selected for presentations at the American College of Rheumatology (“ACR”) 2018 Annual Meeting being held October 19-24, 2018 in Chicago, Illinois. Read more >>